Last reviewed · How we verify

Candel Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Candel Therapeutics, Inc. pipeline: 0 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
aglatimagene besadenovec + valacyclovir aglatimagene besadenovec + valacyclovir phase 3 Oncolytic immunotherapy IL-12 expression; adenovirus replication machinery Oncology
Placebo + valacyclovir Placebo + valacyclovir phase 3 Antiviral nucleoside analog Herpes simplex virus DNA polymerase Oncology
AdV-tk AdV-tk phase 3 Oncolytic virus Tumor cells (HSV-tk prodrug activation pathway) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Aptose Biosciences Inc. · 1 shared drug class
  2. Precigen, Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Candel Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Candel Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/candel-therapeutics-inc. Accessed 2026-05-16.

Related